Pacira Pharmaceuticals buy Raymond James
Start price
20.12.23
/
50%
€29.60
Target price
20.12.24
€38.31
Performance (%)
-16.22%
Price
03.05.24
€25.00
Summary
This prediction is currently active. The price of Pacira Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -16.22%. This prediction currently runs until 20.12.24. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | 4.167% | 4.167% |
| iShares Core DAX® | -0.922% | -1.078% |
| iShares Nasdaq 100 | 0.371% | -0.556% |
| iShares Nikkei 225® | 2.224% | -2.825% |
| iShares S&P 500 | -0.026% | -0.788% |
Comments by Raymond_James for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat